Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Thromb Res ; 223: 24-33, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36702064

RESUMO

INTRODUCTION: Studies exploring alterations in blood coagulation and platelet activation induced by COVID-19 vaccines are not concordant. We aimed to assess the impact of four COVID-19 vaccines on platelet activation, coagulation, and inflammation considering also the immunization dose and the history of SARS-CoV-2 infection. METHODS: TREASURE study enrolled 368 consecutive subjects (161 receiving viral vector vaccines -ChAdOx1-S/Vaxzevria or Janssen- and 207 receiving mRNA vaccines -Comirnaty/Pfizer-BioNTech or Spikevax/Moderna). Blood was collected the day before and 8 ± 2 days after the vaccination. Platelet activation markers (P-selectin, aGPIIbIIIa and Tissue Factor expression; number of platelet-monocyte and -granulocyte aggregates) and microvesicle release were analyzed by flow cytometry. Platelet thrombin generation (TG) capacity was measured using the Calibrated Automated Thrombogram. Plasma coagulation and inflammation markers and immune response were evaluated by ELISA. RESULTS: Vaccination did not induce platelet activation and microvesicle release. IL-6 and CRP levels (+30%), D-dimer, fibrinogen and F1+2 (+13%, +3.7%, +4.3%, respectively) but not TAT levels significantly increased upon immunization with all four vaccines, with no difference among them and between first and second dose. An overall minor post-vaccination reduction of aPC, TM and TFPI, all possibly related to endothelial function, was observed. No anti-PF4 seroconversion was observed. CONCLUSION: This study showed that the four COVID-19 vaccines administered to a large population sample induce a transient inflammatory response, with no onset of platelet activation. The minor changes in clotting activation and endothelial function might be potentially involved at a population level in explaining the very rare venous thromboembolic complications of COVID-19 vaccination.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Humanos , Coagulação Sanguínea , Ativação Plaquetária , SARS-CoV-2
2.
Assist Inferm Ric ; 40(4): 213-220, 2021.
Artigo em Italiano | MEDLINE | ID: mdl-35138303

RESUMO

. Radial artery occlusion after a radial access procedure: pilot study comparing eco Doppler and Inverse Barbeau Test assessments. INTRODUCTION: Radial artery occlusion (RAO) after a radial access procedure can compromise the distal flow and hamper any possible reuse of the radial artery. Ultrasound examination is the gold standard for identifying RAO, but requires special equipment and expertise. An indirect test to estimate radial flow is the Inverse Barbeau Test (IBT), which evaluates the radial oximetry waveform during ulnar artery compression. AIM: To determine the incidence of RAO and to compare the results obtained with the ultrasound and IBT tests. METHODS: Between November 2017 and February 2018, 50 patients undergoing radial access angiography were enrolled. Radial flow was assessed using both ultrasound and IBT, at three times: before the procedure (T0), at 24 hours (T1) and at 30 days (T2). RESULTS: The incidence of RAO obtained by ultrasound was no cases at T0, 3 (6%) at T1 and 1 (2.4%) at T2. IBT identified 14 (28%), 33 (66%) and 10 (23.8%) cases respectively. Some cases with no occlusion with the ultrasounds, 14 (28%), 30 (60%) and 9 (21.4%) respectively, resulted occluded by IBT. CONCLUSIONS: The incidence of RAO is comparable to that reported in the literature (<10%). The IBT correctly identifies the presence of flow, but overestimates radial occlusion.


Assuntos
Arteriopatias Oclusivas , Artéria Radial , Humanos , Incidência , Projetos Piloto , Artéria Radial/diagnóstico por imagem , Artéria Ulnar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...